CERO THERAPEUTICS HOLDINGS, INC.: 10-K filed 2024-04-02

Name: CERO THERAPEUTICS HOLDINGS, INC.: 10-K filed 2024-04-02
Creator: CERO THERAPEUTICS HOLDINGS, INC.

What CERO THERAPEUTICS HOLDINGS, INC. reported in its annual report filed 2024-04-02 (fiscal FY 2023): 18 published measures, 38 facts as tagged in accession 0001213900-24-029051.

This filing

Form: 10-K (annual report)
Filed: 2024-04-02
Fiscal period: fiscal FY 2023
Accession: 0001213900-24-029051 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CERO THERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-12-31	8,560,610	USD
At 2022-12-31	42,367,032	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-12-31	14,323,421	USD
At 2022-12-31	39,898,341	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-12-31	-14,199,122	USD
At 2022-12-31	-11,000,154	USD
At 2021-12-31	-7,669,865	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-12-31	96,873	USD
At 2022-12-31	475,870	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,536,233	USD	365
2022-01-01 to 2022-12-31	-667,736	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-1,523,604	USD	365
2022-01-01 to 2022-12-31	-1,092,247	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-32,576,627	USD	365
2022-01-01 to 2022-12-31	-138,703,878	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-7,944,740	USD	365
2022-01-01 to 2022-12-31	180,839,396	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-12-31	-14,199,669	USD
At 2022-12-31	-11,000,701	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	94,819	USD	365
2022-01-01 to 2022-12-31	599,159	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,932,985	USD	365
2022-01-01 to 2022-12-31	-2,905,441	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-12-31	5,173,421	USD
At 2022-12-31	30,748,341	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	33,481,627	USD	365
2022-01-01 to 2022-12-31	139,353,878	USD	365

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-12-31	96,873	USD
At 2022-12-31	42,141,844	USD
At 2021-12-31	1,098,573	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-12-31	27,426	USD
At 2022-12-31	225,188	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2,441,414	USD	365
2022-01-01 to 2022-12-31	-68,577	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	2,892,935	USD	365
2022-01-01 to 2022-12-31	2,841,391	USD	365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-94,819	USD	365
2022-01-01 to 2022-12-31	-599,159	USD	365

Inspect the source

Entity: CERO THERAPEUTICS HOLDINGS, INC. / CIK 0001870404
Captured: 2026-09-19T11:21:59.403Z
SEC response SHA-256: 8c8c2bd97bf9d18c6c5d6af2474c4302fa2e6a98d7edbc511d62e8f44742c0ac

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001870404.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))